HUMAN RECOMBINANT INSULIN MARKET ANALYSIS

Human Recombinant Insulin Market, by Product Type (Rapid-Acting Human Insulin, Short-Acting Human Insulin, Intermediate-Acting Human Insulin, Long-Acting Human Insulin, and Premixed Human Insulin), by Brand (Humalog, Novolog, Apidra, Humulin R, Novolin R, Humulin N, Novolin N, Levemir, Lantus, Humalog Mix, Novolog Mix, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jul 2022
Code : CMI1797
Pages :205
Formats :
Excel and PDF
Industry : Biotechnology

Human Recombinant Insulin MarketSize and Trends

The global human recombinant insulin market is estimated to be valued at US$ 36,134.5 million in 2022 and is expected to exhibit a CAGR of 7.3% during the forecast period (2022-2030).

Figure 1. Global Human Recombinant Insulin Market Share (%), by Product Type, 2022

The increasing investment in diabetes research activities is expected to drive the growth of the global human recombinant insulin market.

Figure 2.Global Human Recombinant Insulin Market Share (%), by Region, 2022

Increasing prevalence of diabetes worldwide is expected to drive growth of the global human recombinant insulin market is expected to drive the market growth.

Increasing prevalence of diabetes worldwide is expected to drive growth of the human recombinant insulin market is expected to drive the market growth over the forecast period. For instance, according to data published by the World Health Organization (WHO) in 2019, diabetes was the direct cause of 1.5 million deaths and 48% of all deaths due to diabetes occurred before the age of 70 years.